OverviewChartProfileKey statisticsFinancialsNews
Derivatives
TraderScreen

Pfizer INC PFIZER ORD (CDI)/  US7170811035  /

London Domestic
2024-05-24  6:46:10 PM Chg. - Volume Bid3:42:26 PM Ask3:42:26 PM Market Capitalization Dividend Y. P/E Ratio
28.7500USD - 30,720
Turnover: 87,521.6140		 28.0000Bid Size: 150 30.7000Ask Size: 600 166.6 bill.USD 5.61% 77.37
TeleTrader 09-14 Pfizer reports positive data from experimental drug study
GlobeNewswire 09-03 Valneva and Pfizer Report Further Positive Phase 2 Booster Results for Lyme Disease Vaccine Candidat...
TeleTrader 08-27 Pfizer launches digital platform to 'simplify' healthcare access
TeleTrader 08-22 FDA okays Moderna, Pfizer updated vaccines
GlobeNewswire 08-22 Pfizer and BioNTech Receive U.S. FDA Approval & Authorization for Omicron KP.2-adapted COVID-19 Vacc...
GlobeNewswire 08-16 Pfizer and BioNTech Provide Update on mRNA-based Combination Vaccine Program Against Influenza and C...
TeleTrader 07-30 Pfizer's Q2 revenue rises by 2% to $13.3B
GlobeNewswire 07-17 Phase 3 VALOR Lyme Disease Trial: Valneva and Pfizer Announce Primary Vaccination Series Completion ...
TeleTrader 07-11 Pfizer advances once-daily version of weight loss pill
TeleTrader 07-09 Pfizer's chief scientific officer to leave after 15 years
GlobeNewswire 06-27 Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron JN.1-adapted COVID-19 Vaccine in the E...
GlobeNewswire 06-05 Relay Therapeutics Announces Clinical Trial Collaboration with Pfizer to Evaluate Atirmociclib in Co...
GlobeNewswire 06-03 Valneva Announces Publication of Lyme Disease Phase 2 Trials in the Lancet Infectious Diseases
GlobeNewswire 05-16 Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combinatio...
TeleTrader 05-01 Pfizer's Q1 revenue drops 20% to $14.9 billion
GlobeNewswire 04-30 TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervica...
GlobeNewswire 03-22 Gastroenterologists Slow to Adopt Eli Lilly’s Omvoh, Pfizer’s Velsipity, and Takeda’s subcutaneous ...
GlobeNewswire 03-20 Valneva Reports Full Year 2023 Results and Provides Business Updates and Outlook
GlobeNewswire 03-07 BNTX DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages BioNTech SE Investors to Secure Counsel B...
GlobeNewswire 03-07 SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in BioNTe...
GlobeNewswire 03-05 LAVA Announces Clinical Development Milestone Achieved by Pfizer for PF-08046052 (formerly SGN-EGFRd...
GlobeNewswire 02-28 SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in BioNTe...
GlobeNewswire 02-28 BNTX DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages BioNTech SE Investors to Secure Counsel B...
GlobeNewswire 02-27 Arch Biopartners Has Pre-IND Meeting With FDA to Discuss Repurposing Cilastatin as a New Treatment t...
GlobeNewswire 02-23 Charting New Paths: Non-TNF's Evolving in Rheumatoid Arthritis Market